This is a working overview of TP-7, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
==== Direct-acting antivirals ==== The term direct-acting antiviral (DAA) was first coined to describe anti-hepatitis C drugs that directly targeted viral processes. Prior antiviral regimens were designed to supplement the immune system's ability to fight infection as a whole. In comparison, DAAs directly disrupt hepatitis C virus entry and replication processes by interfering with viral proteins. Prior to the discovery of DAAs, hepatitis C was treated with a combination of interferon and ribavirin which increase expression of genes involved in the antiviral immune response. DAAs drastically improved treatment outcomes by increasing safety and efficacy through increased specificity, resulting in increased sustained virological response (SVR) rates. SVR is achieved when hepatitis C virus RNA remains undetectable 12–24 weeks after treatment ends. Once SVR is achieved, treatment is considered a success. Combination therapy of interferon and ribavirin has a SVR rate of approximately 65%. In contrast, SVR rates in clinical trials for numerous DAAs can be as high as 95%. The DAA drugs against hepatitis C are taken orally, as tablets, for 8 to 12 weeks and the antiviral prescribed depends on the strain (genotypes) of hepatitis C virus that are causing the infection. Both during and at the end of treatment, blood tests are used to monitor the effectiveness of the treatment and subsequent cure. The DAA commonly used combination drugs used to treat hepatitis C viral infections include:
=== Digital ion trap === The digital ion trap (DIT) is a quadrupole ion trap (linear or 3D) that differs from conventional traps by the driving waveform. A DIT is driven by digital signals, typically rectangular waveforms that are generated by switching rapidly between discrete voltage levels. Major advantages of the DIT are its versatility and virtually unlimited mass range. The digital ion trap has been developed mainly as a mass analyzer.
==== HIV protease binding ==== Ritonavir is a pseudo-C2-symmetric peptidomimetic inhibitor of the HIV-1 protease. It acts as a tight-binding, active-site titrant with an inhibition constant (Ki) of 15 pM. At a structural level, the P3 isopropylthiazolyl group of ritonavir projects directly into the enzyme's active site to form critical hydrophobic interactions with the side chain of the Valine-82 (V82) residue. Resistance to ritonavir occurs when the viral protease gene develops mutations that distort this binding pocket; these amino acid substitutions generally occur in a stepwise fashion at specific positions, including V82A, V82F, V82T, and V82S.
=== Explosives industry === At the 1936 meeting of the American Chemical Society, professor Edward Bartow of the University of Iowa presented a commercially viable means of extracting large amounts of inositol from the phytic acid naturally present in waste corn. As a possible use for the chemical, he suggested 'inositol nitrate' as a more stable alternative to nitroglycerin. Today, inositol nitrate is used to gelatinize nitrocellulose in many modern explosives and solid rocket propellants.
Sources: en.wikipedia.org
== Difference between channels and carriers == A carrier is not open simultaneously to both the extracellular and intracellular environments. Either its inner gate is closed, or its outer gate is closed. That is, its inner and outer gates are never open at the same time. In contrast, a channel can be open to both environments at the same time, allowing the molecules to diffuse without interruption. Carriers have binding sites, but pores and channels do not. When a channel is opened, millions of ions can pass through the membrane per second, but only 100 to 1000 molecules typically pass through a carrier molecule in the same time. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.
S-Arrestin is a protein found in mice that binds to rhodopsin to stop its activity, preventing further signaling. S-arrestin binds to G protein-coupled receptors (GPCRs), like rhodopsin, following receptor activation and phosphorylation by G protein-coupled receptor kinases (GRKs). Rhodopsin is found in rod cells of the retina, essential for vision. It detects light and initiates a signaling cascade called phototransduction. However, excessive activation can be harmful, so it must be carefully regulated. The phosphorylation of the receptor's intracellular loops and C-terminal tail creates a high-affinity binding site for S-arrestin. S-arrestin then sterically hinders further G protein coupling, effectively desensitizing the receptor and directing it towards alternative signaling pathways or internalization via clathrin-mediated endocytosis.
=== Neutron source === 252Cf has a number of specialized uses as a strong neutron emitter; it produces 139 million neutrons per microgram per minute. This property makes it useful as a startup neutron source for some nuclear reactors and as a portable (non-reactor based) neutron source for neutron activation analysis to detect trace amounts of elements in samples. Neutrons from californium are used as a treatment of certain cervical and brain cancers where other radiation therapy is ineffective. It has been used in educational applications since 1969 when Georgia Institute of Technology got a loan of 119 μg of 252Cf from the Savannah River Site. It is also used with online elemental coal analyzers and bulk material analyzers in the coal and cement industries. Neutron penetration into materials makes californium useful in detection instruments such as fuel rod scanners; neutron radiography of aircraft and weapons components to detect corrosion, bad welds, cracks and trapped moisture; and in portable metal detectors. Neutron moisture gauges use 252Cf to find water and petroleum layers in oil wells, as a portable neutron source for gold and silver prospecting for on-the-spot analysis, and to detect ground water movement. The main uses of 252Cf in 1982 were, reactor start-up (48.3%), fuel rod scanning (25.3%), and activation analysis (19.4%). By 1994, most 252Cf was used in neutron radiography (77.4%), with fuel rod scanning (12.1%) and reactor start-up (6.9%) as important but secondary uses. In 2021, fast neutrons from 252Cf were used for wireless data transmission.
In nuclear physics, transient equilibrium is a situation in which equilibrium is reached by a parent-daughter radioactive isotope pair where the half-life of the daughter is shorter than the half-life of the parent. Contrary to secular equilibrium, the half-life of the daughter is not negligible compared to parent's half-life. An example of this is a molybdenum-99 generator producing technetium-99 for nuclear medicine diagnostic procedures. Such a generator is sometimes called a cow because the daughter product, in this case technetium-99, is milked at regular intervals. Transient equilibrium occurs after four half-lives, on average.
== Fifth round proper == The draw for the fifth round took place on 30 January 2023 on The One Show at Broadcasting House in Portland Place. The matches took place in the week commencing 27 February 2023. This round included one team from the fourth tier, the lowest-ranked team remaining in the competition: Grimsby Town.
Sources: en.wikipedia.org
=== Quantum dots === Graphene quantum dots (GQDs) keep all dimensions less than 10 nm. Their size and edge crystallography govern their electrical, magnetic, optical, and chemical properties. GQDs can be produced via graphite nanotomy or via bottom-up, solution-based routes (Diels-Alder, cyclotrimerization and/or cyclodehydrogenation reactions). GQDs with controlled structure can be incorporated into applications in electronics, optoelectronics and electromagnetics. Quantum confinement can be created by changing the width of graphene nanoribbons (GNRs) at selected points along the ribbon. It is studied as a catalyst for fuel cells.
Amyloids are formed of long unbranched fibers that are characterized by an extended β-sheet secondary structure in which individual β strands (β-strands) (coloured arrows in the adjacent figure) are arranged in an orientation perpendicular to the long axis of the fiber. Such a structure is known as cross-β structure. Each individual fiber may be 7–13 nanometres in width and a few micrometres in length. The main hallmarks recognised by different disciplines to classify protein aggregates as amyloid is the presence of a fibrillar morphology with the expected diameter, detected using transmission electron microscopy (TEM) or atomic force microscopy (AFM), the presence of a cross-β secondary structure, determined with circular dichroism, FTIR, solid-state nuclear magnetic resonance (ssNMR), X-ray crystallography, or X-ray fiber diffraction (often considered the "gold-standard" test to see whether a structure contains cross-β fibres), and an ability to stain with specific dyes, such as Congo red, thioflavin T or thioflavin S. The term "cross-β" was based on the observation of two sets of diffraction lines, one longitudinal and one transverse, that form a characteristic "cross" pattern. There are two characteristic scattering diffraction signals produced at 4.7 and 10 Å (0.47 nm and 1.0 nm), corresponding to the interstrand and stacking distances in β sheets. The "stacks" of β sheet are short and traverse the breadth of the amyloid fibril; the length of the amyloid fibril is built by aligned β-strands. The cross-β pattern is considered a diagnostic hallmark of amyloid structure.
The publication of medical abbreviations for use in the journals published by the American Medical Association is dictated by the AMA Manual of Style is the style guide of the American Medical Association. Periods are generally not used. Plurals for medical acronyms are represented by affixes a lowercase s with no apostrophe. Arrows may also be used to indicate elevation (↑), diminution (↓), and causation (→, ←).
=== Toxicity === At present, the information needed to determine if HMX causes cancer is insufficient. Due to the lack of information, EPA has determined that HMX is not classifiable as to its human carcinogenicity. The available data on the effects on human health of exposure to HMX are limited. HMX causes CNS effects similar to those of RDX, but at considerably higher doses. In one study, volunteers submitted to patch testing, which produced skin irritation. Another study of a cohort of 93 workers at an ammunition plant found no hematological, hepatic, autoimmune, or renal diseases. However, the study did not quantify the levels of exposure to HMX. HMX exposure has been investigated in several studies on animals. Overall, the toxicity appears to be quite low. HMX is poorly absorbed by ingestion. When applied to the dermis, it induces mild skin irritation but not delayed contact sensitization. Various acute and subchronic neurobehavioral effects have been reported in rabbits and rodents, including ataxia, sedation, hyperkinesia, and convulsions. The chronic effects of HMX that have been documented through animal studies include decreased hemoglobin, increased serum alkaline phosphatase, and decreased albumin. Pathological changes were also observed in the animals' livers and kidneys. Gas exchange rate was used as an indicator of chemical stress in Northern bobwhite quail (Colinus virginianus) eggs, and no evidence of alterations in metabolic rates associated with HMX exposure was observed.
== Reverse vaccinology with Meningococcus B == Attempts at reverse vaccinology first began with Meningococcus B (MenB). Meningococcus B caused over 50% of meningococcal meningitis, and scientists had been unable to create a successful vaccine for the pathogen because of the bacterium's unique structure. This bacterium's polysaccharide shell is identical to that of a human self-antigen, but its surface proteins vary greatly; and the lack of information about the surface proteins caused developing a vaccine to be extremely difficult. As a result, Rino Rappuoli and other scientists turned towards bioinformatics to design a functional vaccine. Rappuoli and others at the J. Craig Venter Institute first sequenced the MenB genome. Then, they scanned the sequenced genome for potential antigens. They found over 600 possible antigens, which were tested by expression in Escherichia coli. The most universally applicable antigens were used in the prototype vaccines. Several proved to function successfully in mice, however, these proteins alone did not effectively interact with the human immune system due to not inducing a good immune response in order for the protection to be achieved. Later, by addition of outer membrane vesicles that contain lipopolysaccharides from the purification of blebs on gram negative cultures. The addition of this adjuvant (previously identified by using conventional vaccinology approaches) enhanced immune response to the level that was required. Later, the vaccine was proven to be safe and effective in adult humans.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.